Skin micro-injector

Bold-Jet aims to revolutionize needle-free injections with a microjet device that enhances safety, minimizes invasiveness, and improves patient adherence to treatments.

Subsidie
€ 150.000
2022

Projectdetails

Introduction

Needle-based injections are very common in modern medicine, notably in ongoing vaccination efforts worldwide. However, needle phobia and infection risks affect patient compliance with medical treatments, while millions of used needles contaminate the environment.

Challenges in Injection Methods

Lastly, the effectiveness of certain drugs increases when injected intradermally, but targeting the dermis is challenging. Thus, new minimal-invasive procedures are needed.

Jet Injectors Overview

Jet injectors are needle-free medical devices that pressurize thin liquid filaments to penetrate the skin. Jet injections have been effective in subcutaneous and intramuscular delivery, ex vivo, and in vivo.

Limitations of Current Jet Injection Technology

However, the expected needle-free revolution for medical treatments has neither been fulfilled nor widely commercialized due to factors such as:

  1. Bruising, a painful consequence of delivering large volumes in a single location.
  2. When using wrong energy settings, or misalignment with respect to the skin, the injected liquid can perfuse other layers.
  3. The rejected liquid splashes back, leading to an incorrect dose delivery, risks of cross-contamination of the injector parts, or splash-back on the caregiver.
  4. Commercial jet injection methods, such as springs or compressed gas, are noisy which can distress the patient.

The Bold-Jet Solution

Hence, there is a need to develop a new way to deliver smaller doses with maximum accuracy in targeting specific skin layers. Bold-Jet is aimed at revolutionizing the experience of people who receive or perform frequent injections by developing for the first time a needle-free device using microjets that is safer, minimally invasive, and eco-friendly.

Benefits of Bold-Jet

By avoiding the use of needles, we can increase adherence to treatments by patients with fear of sharps and expand clinical routes for existing drugs and treatment.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-6-2022
Einddatum30-11-2023
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • UNIVERSITEIT TWENTEpenvoerder

Land(en)

Geen landeninformatie beschikbaar

Vergelijkbare projecten binnen European Research Council

ERC Proof of...

Overcoming limits for pre-clinical small volume liquid delivery into skin and inflammation quantification

This project aims to validate the BuBble Gun injection method using Skin-On-Chip technology for localized drug testing in chronic skin diseases, paving the way for innovative treatment delivery.

€ 150.000
ERC Proof of...

Targeted Respiratory Drug Delivery by Tribo Charged Sprays

Develop a new technology for precise drug delivery to the lungs using charged droplets to prevent coalescence, enhancing treatment efficacy for conditions like lung cancer and COVID-19.

€ 150.000
ERC Advanced...

Foldable, REconfigurable & Jagged devices for enhanced drug Absorption/seeding

The project aims to develop Self-configurable, Proximity Enabling Devices (SPEDs) for efficient oral delivery of protein/peptide drugs by enhancing retention and interaction with the intestinal wall.

€ 2.556.251
ERC Proof of...

Subcutaneous delivery of theranostic cell-based therapies

This project aims to create a biodegradable hydrogel for subcutaneous delivery of simili-CAR NK cells and cytokines to enhance cancer treatment efficacy while reducing IV administration challenges.

€ 150.000

Vergelijkbare projecten uit andere regelingen

EIC Transition

Integrated needle-free injection and sensing using opto-microfluidics

iSENS is developing BoldJet, a portable needle-free injector using thermocavitation microjets for precise, safe, and environmentally friendly medication delivery, enhancing patient compliance and healthcare outcomes.

€ 2.499.999
Mkb-innovati...

Dermaal microinjectie systeem met holle micronaalden voor oa vaccinaties

Dit project onderzoekt de haalbaarheid van een pijnloos micro-injectiesysteem voor nauwkeurige medicatietoediening, met potentieel voor kankervaccinaties en verbeterde vaccinatiecapaciteit.

€ 20.000
Mkb-innovati...

Epinefrine Auto Injector innovation

Dit project onderzoekt een innovatieve, patiënt-specifieke Epinefrine Auto-Injector pen om de effectiviteit en toegankelijkheid van anafylaxiebehandeling te verbeteren.

€ 20.000
Mkb-innovati...

Intravitreal Injector

De IDE Group ontwikkelt een gebruiksvriendelijke intravitreal injector voor maculadegeneratie, waardoor de behandeling eenvoudiger, minder intimiderend en kosteneffectiever wordt.

€ 20.000
EIC Accelerator

AmbiJet: the world’s first and only highly effective plasma-based solution for Europe’s 16 Million periimplantitis patients urgently needing help to avoid losing their dental implant

AmbiJet is a groundbreaking plasma-based technology that effectively eliminates bacteria on dental implants, preventing reinfection and promoting better oral and overall health.

€ 1.389.062